Corporate Dr. Reddy’s Laboratories Ltd., included in 1984, is a huge cap corporate (marketplace cap Rs 72,621.06 crore) running within the pharmaceutical sector.
Key product/earnings segments Reddy’s Laboratories Ltd. contains prescribed drugs, license charges, different running source of revenue, waste chemical substances, services and products earnings and scrap for the 12 months ended 31 March 2022.
For the quarter ended September 30, 2022, the corporate reported a consolidated overall source of revenue of Rs 6372.60 crore, up 4.70% from the former quarter of Rs 6086.80 crore and up 6.34% greater than in the similar quarter closing 12 months, when the full earnings was once Rs 5,992.40 crore. The corporate reported an after-tax web benefit of Rs 1,100.20 crore in the most recent quarter.
Promoter / FII Holdings
As of September 30, 2022, the promoters owned 26.71% of the stocks of the corporate, FII – 25.87%, DII – 24.6%.
(Disclaimer: The suggestions on this phase, or any stories connected to it, are ready by way of a 3rd celebration. Critiques expressed are the ones of the respective authors/organizations. They don’t constitute the perspectives of the Financial Occasions (ET). ET does now not ensure, warrants for, endorses any of its contents and hereby disclaims all warranties, categorical or implied, when it comes to the similar. Please seek the advice of your monetary guide and search impartial recommendation.